TASSI, RENATO
TASSI, RENATO
Medicina Sperimentale e Clinica
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study
2017 Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M
Druggable Targets in Pancreatic Adenocarcinoma
2014 Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E
Emerging drugs in refractory colorectal cancer
2015 Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616)
2018 Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.
2015 Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
2015 Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G.
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S.
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2019 Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S.
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.
2017 Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study
2015 Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E
Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis
2011 Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY
2017 S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
2017 Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S.
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience
2020 Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S | |
| Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study | 2017 | Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M | |
| Druggable Targets in Pancreatic Adenocarcinoma | 2014 | Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E | |
| Emerging drugs in refractory colorectal cancer | 2015 | Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E | |
| Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) | 2018 | Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania | |
| Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. | 2015 | Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S | |
| Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S | |
| HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment | 2015 | Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G. | |
| RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S. | |
| RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2019 | Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S. | |
| Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. | 2017 | Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E | |
| Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study | 2015 | Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E | |
| Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis | 2011 | Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R | |
| THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY | 2017 | S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini | |
| The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. | 2017 | Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S. | |
| Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience | 2020 | Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico |